论文部分内容阅读
目的观察紫杉醇单药治疗老年非小细胞肺癌(NSCLC)的近期疗效及毒副反应,评价其治疗老年NSCLC的安全性。方法 48例经病理或细胞学确诊的老年NSCLC患者。采用紫杉醇135 mg/m2,静脉滴注3 h,d1,21 d为1周期,所有患者均接受2个疗程化疗。结果 48例患者均可评价疗效及毒副反应。部分缓解(PR)19例(39.6%),稳定(SD)23例(47.9%),进展(PD)6例(12.5%),(PR+SD)42例(87.5%)。主要不良反应有骨髓抑制,恶心和呕吐,肌痛和关节痛,脱发,肝功能异常,多为Ⅰ～Ⅱ度反应。结论紫杉醇单药治疗老年(≥65岁)NSCLC疗效较好,毒性低,患者耐受性良好,值得在临床上推广使用。
Objective To observe the short-term curative effect and side effects of paclitaxel monotherapy in the treatment of elderly non-small cell lung cancer (NSCLC) and evaluate its safety in the treatment of elderly NSCLC. Methods Forty-eight elderly patients with pathologically or cytologically diagnosed NSCLC were enrolled. Paclitaxel 135 mg / m2, intravenous infusion of 3 h, d1, 21 d for a cycle, all patients received two courses of chemotherapy. Results 48 patients can evaluate the efficacy and side effects. There were 19 cases (39.6%) of partial remission (PR), 23 cases (47.9%) of stable (SD), 6 cases (12.5%) of progression (PD) and 42 cases (87.5%) of PR + SD. The main adverse reactions are myelosuppression, nausea and vomiting, myalgia and arthralgia, hair loss, abnormal liver function, mostly Ⅰ ~ Ⅱ degree response. Conclusion Paclitaxel monotherapy for the elderly (≥ 65 years) NSCLC better curative effect, low toxicity, patients with good tolerance, it is worth to promote the use of the clinic.